Article Publish Status: FREE
Abstract Title:

Varicella and varicella vaccination in South Korea.

Abstract Source:

Clin Vaccine Immunol. 2014 May ;21(5):762-8. Epub 2014 Mar 26. PMID: 24671555

Abstract Author(s):

Sung Hee Oh, Eun Hwa Choi, Seon Hee Shin, Yun-Kyung Kim, Jin Keun Chang, Kyong Min Choi, Jae Kyun Hur, Kyung-Hyo Kim, Jae Youn Kim, Eun Hee Chung, Soo Young Lee, Su Eun Park, Sungho Cha, Kwang-Nam Kim, Sang Hyuk Ma, Byung Wook Eun, Nam Hee Kim, Dae Sun Jo, Bo Youl Choi, Shin Ah Kim

Article Affiliation:

Sung Hee Oh


With continuing occurrence of varicella despite increasing vaccine coverage for the past 20 years, a case-based study, a case-control study, and an immunogenicity and safety study were conducted to address the impact of varicella vaccination in South Korea. Varicella patients under the age of 16 years were enrolled for the case-based study. For the case-control study, varicella patients between 12 months and 15 years of age were enrolled with one control matched for each patient. For the immunogenicity and safety study, otherwise healthy children from 12 to 24 months old were immunized with Suduvax (Green Cross, South Korea). Fluorescent antibody to membrane antigen (FAMA) varicella-zoster virus (VZV) antibody was measured before and 6 weeks after immunization. In the case-based study, the median age of the patients was 4 years. Among 152 patients between 1 and 15 years of age, 139 children received varicella vaccine and all had breakthrough infections. Clinical courses were not ameliorated in vaccinated patients, but more vaccinated patients received outpatient rather than inpatient care. In the case-control study, the adjusted overall effectiveness of varicella vaccination was 54%. In the immunogenicity and safety study, the seroconversion rate and geometric mean titer for FAMA antibody were 76.67% and 5.31. Even with increasing varicella vaccine uptake, we illustrate no upward age shift in the peak incidence, a high proportion of breakthrough disease, almost no amelioration in disease presentation by vaccination, and insufficient immunogenicity of domestic varicella vaccine. There is need to improve the varicella vaccine used in South Korea.

Study Type : Human Study

Print Options

Key Research Topics

Sayer Ji
Founder of

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022, Journal Articles copyright of original owners, MeSH copyright NLM.